Validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) in the Portuguese population with multiple sclerosis by Sousa, C. et al.
RESEARCH ARTICLE Open Access
Validation of the brief international
cognitive assessment for multiple sclerosis
(BICAMS) in the Portuguese population
with multiple sclerosis
Cláudia Sousa1*† , Mariana Rigueiro-Neves2†, Telma Miranda1, Paulo Alegria3, José Vale3, Ana Margarida Passos2,
Dawn Langdon4 and Maria José Sá1,5
Abstract
Background: The validation of international cognitive batteries in different multiple sclerosis (MS) populations
is essential. Our objective was to obtain normative data for the Portuguese population of the Brief International Cognitive
Assessment for Multiple Sclerosis (BICAMS) and assess its reliability.
Methods: The BICAMS was applied to 105 MS patients and 60 age, gender and education matched healthy controls
(HC). In order to test its reliability, BICAMS was re-administered in a subset of 25 patients after a 7-month interval.
Results: Most participants were women, with a mean age of 37, 21 years and a mean of 14,08 years of education. The
vast majority of the MS patients (92.4%) had the relapsing remitting type, 58.1% were professionally active, mean disease
duration was 6.52 years, median EDSS score was 1.5 (range: 0–6.0) and the median MSSS score was 2.01 (IQR range: 3.83).
The MS group presented significantly higher scores of anxiety and depression than HC and 47,4% had fatigue. The MS
group performed significantly worse than the control group across the three neuropsychological tests, yielding the
following values: SDMT: t(165) = 3.77, p = .000; CVLT-II: t(165) = 2.98, p = .003; and BVMT-R: t(165) = 2.94, p = .004.
The mean raw scores for Portuguese normative data were as follows: SDMT: 58.68 ± 10.02; CVLT-II: 60.47 ± 10.12;
and BVMT-R: 24.68 ± 5.52. Finally, test–retest reliability coefficients for each test were as follows: SDMT: r = .90;
CVLT-II: r = .71; and BVMT-R: r = .84.
Conclusions: The Portuguese version of BICAMS here in described is a reliable monitoring instrument for identifying
MS patients with cognitive impairment.
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Background
Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system that
can impair any body function, including cognition [1].
Cognitive dysfunction affects 40 to 70% patients [2, 3].
Irrespective of age and gender [3, 4], may occur at all
stages of the disease, even at the very early beginning [5,
6] and definitely impacts the lives of MS patients and
their families [3, 7, 8].
The characteristic pattern of cognitive impairment in
MS has been described early on to include memory, in-
formation processing efficiency, executive functioning,
attention and processing speed [1]. However, the cogni-
tive domains most likely to be affected in MS are infor-
mation processing speed and memory, whilst visual
processing and executive function are less likely to be
impaired and language is largely intact [1, 9–12].
The most frequently used neuropsychological batteries
for patients with MS such us, the Brief Repeatable Bat-
tery of Neuropsychological tests and the Minimal
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Assessment of Cognitive Function in MS, require spe-
cialized technical and human resources and take a con-
siderable time for evaluation in the daily clinical setting
[1, 13]. Recently, the Brief International Cognitive As-
sessment for MS (BICAMS) was developed and recom-
mended as a validated and standardized international
screening test, because it is an easier assessment tool
that can be administered by a technician who is not a
specialist in neuropsychology and lasts only about
15 min to apply [14, 15]. Besides, the three instruments
that compose BICAMS – Symbol Digit Modalities Test
(SDMT) [16], California Verbal Learning Test (CVLT-II)
[17] and Brief Visuo-spatial Memory Test Revised
(BVMT-R) [18] – have previously been shown to have
good psychometric properties.
The aims of this study are to describe the normative
values of the Portuguese version of the BICAMS with
gender, age and education corrections and to test the
validity of this battery in a sample of Portuguese patients
with MS.
Methods
Participants
A group of 105 patients with MS diagnosed according to
the McDonald criteria [19] and a control group of 60
age, gender and education matched healthy subjects
(HC), entered this study, and conducted in the period
2015–2016.
The MS patients were consecutively recruited at the
MS Clinics from two hospitals located in separate re-
gions of the country, Hospital de São João (Oporto;
North) and Hospital Beatriz Ângelo (Loures; South),
whereas the HC group was recruited from the commu-
nity and among relatives and friends of MS patients. All
participants were aged between 17 and 69 years and they
were fluent in Portuguese as first language.
Exclusion criteria were current or past neurological
disorder other than MS, presence of major psychiatric
illness, history of learning disability, history of serious
head trauma, presence of alcohol or drug abuse, relapse
and/or corticosteroid use within 4 weeks preceding the
neuropsychological assessment. HC were also required
to present scores > 21 on Montreal Cognitive Assess-
ment Portuguese version (MoCA) [20, 21].
The study was approved by the ethical committees of
both hospitals. All the participants, from MS group and
HC, volunteered to participate in this study, giving writ-
ten informed consent.
Procedures
An initial demographic interview was conducted. This
was based on a common script that included a demo-
graphic questionnaire, medical history, drinking and
drug habits and present health status. The MS data, such
as type, duration, and degree of disability and severity, as
assessed by the Expanded Disability Status Scale (EDSS)
[22] score and the Multiple Severity Status Score (MSSS)
[23], respectively, were obtained in the clinical protocols.
Then, participants underwent the BICAMS battery
[14], which included the oral version of Symbol Digit
Modalities Test (SDMT) [16], the learning trials from
the California Verbal Learning Test-II (CVLT-II) [17]
and the Brief Visuo-spatial Memory Test-Revised learn-
ing trials (BVMT-R) [18].
The SDMT [16] examines sustained attention, concen-
tration and processing speed. In the oral version, the
participant examines a series of nine meaningless geo-
metric symbols, which are labeled from 1 to 9. Then,
during 90 s the participant is instructed to say the corre-
sponding number to each symbol, as rapidly as possible.
The test score corresponds to the number of correct
responses.
The CVLT-II [17] is a measure of verbal learning and
memory. The test begins with the examiner reading a list
of 16 words to the patient and then he/she is asked to
report as many of the items as possible, in any order.
After recall is recorded, the entire list is read again
followed by a second attempt at recall. Altogether, there
are five learning trials. The outcome measure is the total
number of recalled items over the five learning trials.
The BVMT-R [18] is a measure of visuo-spatial learning
and memory. The participant is exposed to a matrix of six
simple abstract designs for 10 s followed by an unaided re-
call; we used the form 1 of the original test. After that, the
participant is asked to render the designs using paper and
pencil, taking as much time as needed for reproduction.
The scoring criterion is based on location and accuracy of
each design (from 0 to 2, maximum total score for each
array 12). The outcome measure of this test corresponds
to the total recall score across the three trials.
The validation was conducted per the international
standards given by the expert consensus committee [15].
As the first step, the CVLT-II list of words were trans-
lated and re-translated from English to Portuguese and
vice versa respectively; the other two tests did not re-
quire translation due to their nature. In the second step,
the test instructions were translated into Portuguese.
In both groups, anxiety and depression symptoms
were also measured using the Portuguese version of
Hospital Anxiety and Depression Scale (HADS) [24]. In
the MS group the level of fatigue was measured with the
Modified Fatigue Impact Scale (MFIS) [25–27].
“The participants of both groups were asked to return
for a follow-up session to allow for test–retest reliability
analyses. A subgroup of 26 patients and 13 HC returned
after a mean time of 7 months and all the tests adminis-
tered in the first session were repeated in the same man-
ner and in the same order.”
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Well-trained clinical psychologists conducted all ses-
sions and the tests were applied in a standardized way
and in a fixed order. The mean time for BICAMS appli-
cation was 15 min, as described [14, 15].
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (IBM SPSS), version
23.0. Descriptive statistics (e.g., mean, standard devi-
ation, median, interquartile range and percentages) were
used for demographic characterization of both groups.
Student’s t-test for independent samples was used to
analyze the differences between groups, at the level of p
< .05. The values shown in the tables are bilateral
p-values. The effect sizes of those differences were calcu-
lated using Cohen’s d. Spearman’s correlations (Ρ) were
used to analyze reliability measures and the relationship
between BICAMS, HADS and MFIS results. Raw scores
were analyzed for the full sample and Z-scores were cal-
culated. Multiple regression analysis was used to pro-
duce normative data.
Results
Demographics and MS characteristics
The groups were similar with regard to age (MS group:
M = 38.26 years±11.03; HC: M = 36.17 years ±12.01,
p = .63), gender (MS group: %Female = 66.7; HC: %Fe-
male = 58.3, p = .28) or number of educational years (MS
group: M = 13.55 ± 3.71; HC: M = 14.62 ± 3.47, p = .42).
With respect to professional status, the majority of sub-
jects were employed, with a much higher proportion of
HC than MS, as is usually reported (n = 56, 94.9%; n =
61, 58.1%, respectively). In the MS group, 92,4% (n = 97)
of patients had the relapsing remitting type and 3,8%
(n = 4) secondary progressive type and 3,8% (n = 4) clin-
ically isolated syndrome. The average disease duration
was 6.52 years (SD = 5.95) and the median EDSS score
was 1.5 (range: 0–6.0). The MSSS score, calculated in
patients from 1 to 30 years of disease duration (n = 95),
had a median value of 2.01 (IQR range: 3.83).
Criterion-related validity: Group differences
Means, standard deviations and t test’s for independent
samples from the three tests are presented in Table 1.
The results showed that MS group performed signifi-
cantly worse than the HC group on all measures.
Cohen’s d was analyzed for each neuropsychological test
and were satisfactory: SDMT - 0.65 (large); CVLT-II -
0.49 (medium); BVMT-R - 0.45 (medium) [28].
Reliability: Test-retest
The test–retest reliability data obtained in a subgroup of
MS patients are presented in Table 2. The test-retest re-
liability coefficients showed a strong to a very strong and
significant effect for all BICAMS tests.
The test-retest results in the HC were not considered
in view of the low number of cases.
Regression based-norms
To obtain a regression-based normative model for
BICAMS, the distribution of the SDMT, CVLT-II and
BVMT-R raw scores was analyzed for the complete sam-
ple and the Z scores were calculated. The raw scores
were then converted into scaled scores (M = 10 and SD
= 3), as presented in Table 3. For each test a multiple re-
gression analysis with a stepwise method using the
scaled scores as dependent variable and age, gender and
education as predictors was performed. Education was
introduced as the number of regular academic school
years that the participant successfully completed. As
some studies suggest that there is a curvilinear relation-
ship between demographic variables and cognitive func-
tion [29], the quadratic term of age and education were
also introduced as predictors. These results allow us to
detect which variables contributed significantly to ex-
plain each of the scaled neuropsychological test scores.
The T-scores corrected for education, age and gender
were generated through a procedure suggested by Diehr
and colleagues [30]. Therefore, another multiple regres-
sion (enter method) with each of the BICAMS test
scaled scores as the dependent variable and the signifi-
cant predictors of each test was performed. The
non-standardized predicted values of this equation were
saved and a new variable was calculated corresponding
to the difference between an individual’s actual and pre-
dicted scale score (i.e., the residual) divided by the stand-
ard deviation of those residuals. These values were then
rescaled for a T-score (M = 50 and SD = 10).
Finally, another multiple regression analysis with cor-
rected T-score as the dependent variable was performed
to generate each test normative formula for the
Table 1 Group differences on BICAMS measures
MS
(N = 105)
HC
(N = 60)
t P
SDMT 51.77 (11.20) 58.68 (10.02) 3.77 0.000
CVLT-II 55.05 (11.84) 60.47 (10.12) 2.98 0.003
BVMT-R 21.72 (7.27) 24.68 (5.52) 2.94 0.004
Table 2 Test–retest means and correlations for MS group (n = 26)
Time 1 Time 2 Spearman’s
correlation
P
Mean SD Mean SD
SDMT 50.96 11.56 53.92 13.99 0.90 < 0.001
CVLT-II 57.08 12.75 57.31 17.44 0.71 < 0.001
BVMT-R 22.00 7.43 25.12 6.94 0.84 < 0.001
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Portuguese population. The final formula to calculate
the T-scores for each of BICAMS’s test are presented
below:
SDMT T score ¼ 10:511þ 0:007 age2 
þ −0:966 years of educationð Þ
þ 4:138 scaled scoreð Þ
CVLT−II T score ¼ 3:195þ 0:006 age2 
þ 3:761 scaled scoreð Þ
BVMT−R T score ¼ −8:004þ 0:514 ageð Þ
þ 3; 833 scaled scoreð Þ
In determining impairment, the 5th percentile value
based on the performance of healthy control sample was
calculated for each test. Participants were considered im-
paired if their score was equal of below the percentile
5thof the control group (results are presented on the
Table 4) [31]. Then, using the previously reported cri-
teria of impairment defined by “one or more abnormal
tests” [32, 33], it was found that 24.8% of the MS sample
was impaired at baseline.
Analysing the degree of disability assessed by EDSS
and cognitive performance, we found significant correla-
tions with all cognitive tests (SDMT: −.497, p = .000;
CVLT: −.334, p = .000; BVMT: −.275, p = .005).
Regarding anxiety and depression symptoms, it was
found that MS group presented higher scores on these
measures than HC, and that these differences were statis-
tically significant: anxiety (MS group: M = 7.85 ± 4.51; HC:
M = 6.32 ± 3.00, t = − 2.348; p = .20) and depression (MS
group: M = 5.14 ± 3.95; HC: M = 3.18 ± 2.57). Anxiety
symptoms were found to be more frequent (n = 56; 53.3%)
than depression symptoms (n = 29; 27.6%) in MS patients.
In the MS group depression symptoms had a modest sig-
nificantly negative effect only on CVLT-II results (R –
0.196; p = .45), whereas anxiety was not significantly corre-
lated with any BICAMS test. The assessment with the
MFIS scale (n = 95) showed that fatigue was present in 50
MS patients (47,4%) and was significantly correlated with
the EDSS score (R – .279; p = .006), and with anxiety (R –
.631; p = .0001) and depression symptoms (R – .754; p
= .0001). Conversely, fatigue was negatively correlated
with SDMT score (R – .266; p = .009); similar results were
observed in both MFIS subscales, physical (M= 18.04 ±
9.66; R-.289; p = .005) and cognitive (M = 17.84 ± 10.21;
R-.203; p = .049).
Discussion
An international consensus committee of experts re-
cently recommended a short battery of tests for cogni-
tive assessment in MS that allows monitoring of
cognition over time and is a fast and reliable instrument
that may be administered by healthcare professionals
with no specific experience in neuropsychological test-
ing. According to the international standards for valid-
ation [15], several validation studies of BICAMS have
been carried out in different cultures and languages,
with the aim of making this psychometric tool more
solid and internationally applicable. Up to now, there ex-
ists normative data for populations of several countries,
such as Czech Republic [32], Italy [34], Hungary [35],
Ireland [36], Brazil [37], Lithuania [38] Argentina [39],
Canada [33], Greece [31], Belgium [40], Japan [41] and
Turkish [42].
The current study followed the recommendations and
standards of the BICAMS consensus committee [14, 15]
and is the first to publish the Portuguese normative data
for SDMT, CVLT-II and BVMT-R. Our results showed
that MS group performed significantly worse than HC
group on all measures (SDMT, CVLT-II and BVMT-R),
a finding that is in agreement with the other recently
published validations. These differences were more
marked in the SDMT and CVLT-II than the BVMT-R,
Table 3 Raw score to scaled score conversions for the BICAMSs
tests
Scaled score SDMT CVLT-II BVMT-R
1 – 0–21 –
2 0–20 22–27 1–3
3 21–24 28–33 4–5
4 25–27 34–37 6–8
5 28–33 38–41 9–10
6 34–37 42–44 11–14
7 38–40 45 15
8 41–45 46–49 16–17
9 46–49 50–53 18–20
10 50–53 54–57 21–22
11 54–57 58–60 23–25
12 58–61 61–64 26–27
13 62–65 65–68 28–30
14 66–69 69–72 31–32
15 70–73 73–76 33–34
16 74–76 77–79 –
17 77–78 – –
Table 4 The prevalence of cognitive impairment in MS patients
according to the 5th percentile value of HC on BICAMS tests
5th Percentile value for HC
on each test
Percentage of MS patients under
5th percentile
SDMT 38 14.3%
CVLT-II 41 9.5%
BVMT-R 12 11.4%
Sousa et al. BMC Neurology  (2018) 18:172 Page 4 of 7
and similar results were found by O’Connell and col-
leagues (2015), Spedo and colleagues (2015) and Vanotti
and colleagues (2016). Test-retest reliability in our popu-
lation fits the recommended international standards for
BICAMS validation [14]. Test–retest reliability for raw
scores was adequate to excellent for all the three tests in
this validation; more than .80 in SDMT and BVMT, rep-
licating prior finds [33, 34]. Yet our results are lower
than those of Vanotti and colleagues (2016). In addition
we confirmed that the SDMT has particularly high
test-retest reliability. We used a wider time span than
other authors [37, 40] in order to avoid the learning ef-
fect, since at both evaluation times the same forms were
applied.
The BICAMS tasks were able to identify cognitive im-
pairment in 24.8% of MS patients using the criteria of
impairment defined by one or more abnormal tests. This
is a lower value than those found in other studies, which
ranged from 47.3 to 58% [31–33, 35, 36]. This result
may reflect the characteristics of our MS sample, which
were mainly RRMS and rather early cases (mean disease
duration 6.5 years) and a correspondingly low level of
physical disability, median EDSS 1.5 [31–33, 36]. The
lower level of disability in our sample is further sup-
ported by our MSSS data [23].
We found a significant correlation between EDSS and
cognitive performance in the three tests used, that is, the
higher the EDSS score the worse the cognitive test
performance.
Regarding anxiety and depression symptoms, we found
that the MS group also presented with higher scores on
these measures then the HC, fitting the results of other
BICAMS validation studies [32, 33, 37]. The Hungarian
BICAMS validation reported a negative correlation of fa-
tigue with all BICAMS tests [31]. In our study an associ-
ation with fatigue was only seen in the SDMT test,
possibly reflecting the lower fatigue in our patients as
well as the lower physical disability.
This study was some limitations. First, follow-up as-
sessments were done in a low number of cases, espe-
cially in the HC group, which is due to the fact that
some individuals live far from the Hospital and incur
additional personal costs. Another limitation is the fact
that effect size for CVLT and BVMT-R although satisfac-
tory, is on the threshold of the effect size classified as
medium.
Conclusions
In conclusion, our study provides the Portuguese
BICAMS standards for use with MS patients and
evidences the strong psychometric properties of the
Portuguese BICAMS version. The normative data of the
BICAMS for the Portuguese population enables the use
of the battery in clinical practice, for longitudinal patient
assessments and as an outcome measure of cognitive
functioning in clinical trials. Future prospective stud-
ies with larger samples of MS patients, with different
types of disease evolution, will certainly add valuable
information concerning the clinical applicability of the
Portuguese BICAMS version.
Abbreviations
BICAMS: Brief International cognitive assessment for multiple sclerosis; BRB-
N: Brief repeatable battery of neuropsychological tests; BVMT-R: Brief visuo-
spatial memory test – revised; CI: Cognitive impairment; CVLT-II: California
verbal learning test – II; EDSS: Expanded disability status scale; HADS: Hospital
anxiety and depression scale; HC: Healthy subjects; IBM SPSS: Statistical package
for the social sciences; MACFIMS: Minimal assessment of cognitive function
in multiple sclerosis; MFIS: Modified fatigue impact scale; MoCa: Montreal
cognitive assessment; MS: Multiple sclerosis; MSSS: Multiple severity status score;
SDMT: Symbol digit modalities test
Acknowledgements
The authors would like to thank all participants of this study.
An earlier version of this paper was presented at the ECTRIMS-ACTRIMS
Meeting, Paris, France, 25–28 October 2017. The abstract of the e-Poster
was published in the Multiple Sclerosis Journal (2017): 23: (S3): 680 – 975.
http://journals.sagepub.com/doi/10.1177/1352458517731285.
Availability of data materials
The datasets used and analysed during the current study are available from
the corresponding author on reasonable request.
Funding
This work was funded by an unrestricted educational grant from Bayer, which
had any role in the study, namely in its design, sample collection, analyses and
interpretation of data and in the writing of the manuscript.
Authors’ contributions
CS contributed in study concept and design, drafting and revising the
manuscript and in the acquisition and interpretation of data. MRN contributed
in study concept and design, drafting and revising the manuscript, in the
acquisition and interpretation of data and statistical analysis. TM contributed in
the acquisition of data and statistical analysis. PA and JV contributed in patient
recruitment, acquisition of clinical data and revising the manuscript. AMP
contributed in study concept and design, revising the manuscript, in the
interpretation of data and statistical analysis. DL contributed in study concept
and design and in revising the manuscript. MJS contributed in study concept
and design, drafting and revising the manuscript, in the analysis and
interpretation of data and study supervision. All authors read and approved the
final manuscript.
Ethics approval and consent to participate
All patients and all healthy control subjects provided written informed
consent to participation in the study. The Ethics Committees of Centro
Hospital S. João, Oporto and Ethics Committees Hospital Beatriz Ângelo,
Loures, granted approval for the research project.
Consent for publication
Not applicable.
Competing interests
MJS has received consulting/speaker fees from Bayer, Biogen, CSL Behring,
Merck, Novartis, Roche, Sanofi and Teva.
DL has participated in speaker bureau for Bayer, Merck, Almirall, Execemed,
TEVA, Roche, Novartis, Biogen, Sanofi; has had consultancy from Novartis,
Bayer, Merck, Biogen, TEVA, Sanofi; has had research grants from Bayer,
Merck, Novartis, Biogen. All are paid into DL’s institution.
The other authors have nothing to disclose regarding this study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Sousa et al. BMC Neurology  (2018) 18:172 Page 5 of 7
Author details
1MS Clinic, Department of Neurology, Centro Hospitalar São João Porto,
Alameda Prof. Hernâni Monteiro, 4200 – 319 Porto, Portugal. 2BRU-IUL,
Instituto Universitário de Lisboa (ISCTE-IUL), Lisbon, Portugal. 3Department of
Neurology, Hospital Beatriz Ângelo, Loures, Portugal. 4Department of
Psychology, Royal Holloway, University of London, London, UK. 5Faculty of
Health Sciences, University Fernando Pessoa, Porto, Portugal.
Received: 8 May 2018 Accepted: 7 October 2018
References
1. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive impairment in multiple
sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685–91.
2. Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive
changes: a review of cross-sectional and longitudinal studies. J Neurol Sci.
2006;245:1–2.
3. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol. 2011;24(3):
244–9.
4. Glanz BI, Holand M, Gauthier SA, Amunwa EL, Liptak Z, Houtchens MK,
Sperling RA, Khoury SJ, Guttmann CR, Weiner HL. Cognitive dysfunction in
patients with clinically isolated syndromes or newly diagnosed multiple
sclerosis. Mult Scler. 2007;13(8):1004–10.
5. Amato MP, Hakiki B, Goretti B, et al. Association of MRI metrics and
cognitive impairment in radiologically isolated syndromes. Neurology. 2012;
78:309–14.
6. Zipoli V, Goretti B, Hakiki B, et al. Cognitive impairment predicts conversion to
multiple sclerosis in clinically isolated syndromes. Mult Scler. 2010;16:62–7.
7. Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs
of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–36.
8. Sá MJ, Kobelt G, Berg J, Capsa D, Dalén J. European Multiple Sclerosis
Platform. New insights into the burden and costs of multiple sclerosis in
Europe: Results for Portugal. Mult Scler. 2017;23(2-suppl):143–54.
9. Langdon D. Cognitive assessment in MS. Neurodegenerative Disease
Management. 2015;5(6s):43–5.
10. Rimkus MC, Steenwijk MD, Barkhof F. Causes, effects and connectivity
changes in MS-related cognitive decline. Dement Neuropsychology. 2006;
10(1):2–11.
11. Vanotti S, Caceres FJ. Cognitive and neuropsychiatric disorders among MS
patients from Latin America. Multiple Sclerosis: Journal experimental
translational clinical. 2017:1–11.
12. Giedraitiene N, Kaubrys G, Kizlaitiene R. Cognition during and after multiple
sclerosis relapse as assesses with the brief international cognitive
assessment for multiple sclerosis. Sci Rep. 2018;8:8169.
13. Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N,
Weinstock-Guttman B. Validity of the minimal assessment of cognitive function
in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12:549–58.
14. Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S,
Hämäläinen P, Hartung HP, Krupp L, Penner IK, Reder AT, Benedict RH.
Recommendations for a brief international cognitive assessment for
multiple sclerosis (BICAMS). Mult Scler. 2012;18:891–8.
15. Benedict RH, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S,
Hamalainen P, Hartung H, Krupp L, Penner I, Reder AT, Langdon DW. Brief
international cognitive assessment for MS (BICAMS): international standard
for validation. BMC Neurol. 2012;16:55.
16. Smith A. Symbol digit modalities test: manual. Los Angeles, CA: Western
Psychological Services; 1982.
17. Delis DC, Kramer JH, Kaplan E, Ober BA. California verbal learning test,
second edition (CVLT-II). San Antonio, TX: Psychological Corporation; 2000.
18. Benedict RHB. The brief visuospatial memory test revised (BVMT-R). Lutz, FL:
Psychosocial Assessment Resources Inc.; 1997.
19. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Wolinsky
JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald
criteria. Ann Neurol. 2011;69(2):292–302.
20. Nasreddine ZS, Phllips NA, Béridian V, Charbonneau S, Whitehead V, Collin I,
Cummings JL, Chertkow H. The Montreal cognitive assessment, MoCA: a
brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;
53(4):695–9.
21. Freitas S, Simões MR, Alves L, Santana I. Montreal cognitive assessment
(MoCA): normative study for the Portuguese population. J Clin Exp
Neuropsychol. 2011;33(9):989–96.
22. Kurzke JF. Rating neurologic impairment in multiple sclerosis: an expanded
disability status scale (EDSS). Neurology. 1983;33:1444–52.
23. Roxburgh RHSR, Seaman SR, Masterman T, Hensiek AE, et al. Multiple
sclerosis severity score using disability and disease duration to rate disease
severity. Neurology. 2005;64:1144–51.
24. Silva AM, Vilhena E, Lopes A, Santos E, Gonçalves MA, Pinto C, et al.
Depression and anxiety in a Portuguese MS population: association with
physical disability and severity of disease. J Neurol Sci. 2011;306:66–70.
25. Fisk JD, Ritvo PG, Haase DA, Marrie TJ, Schlech WF. Measuring the functional
impact of fatigue: initial validation of the fatigue impact scale. Clin Infect
Dis. 1994;18(Suppl 1):S79–83.
26. Larson RD. Psychometric properties of the modified fatigue impact scale. Int
J MS Care. 2013;15(1):15–20.
27. Gomes LR. Validação da versão portuguesa da Escala de Impacto da
Fadiga Modificada e da Escala de Severidade da Fadiga na Esclerose
Múltipla (Validation of the Portuguese version of the Modified Fatigue
Impact Scale and the Fatigue Severity Scale in Multiple Sclerosis).
Thesis.Minho University. 2011.
28. Cohen J. Statistical power analysis for the behavioral sciences. New York,
NY: Routledge Academic; 1988.
29. Strauss E, Sherman E, Spreen O. A compendium of neuropsychological tests:
administration, norms and commentary. 3rd ed. Oxford, UK: University
Oxford Press; 2006.
30. Diehr MC, Cherner M, Wolfson TJ, Miller SW, Grant I, Heaton RK, the HIV
Neurobehavioral Research Center. The 50 and 100-item short forms of the
paced auditory serial addition task (PASAT): demographic corrected norms
and comparisons with the full PASAT in normal and clinical samples. J Clin
Exp Neuropsychol. 2003;25:571–58.
31. Polychroniadou E, Bakirtzis C, Langdon D, Lagoudaki E, Kesidou E, Theotokis
P, et al. Validation of the brief international cognitive assessment for
multiple sclerosis (BICAMS) in Greek population with multiple sclerosis.
Multiple Sclerosis and Related Disorders. 2016;9:68–72.
32. Dusankova JB, Kalincik T, Havrdova E, Benedict RH. Cross cultural validation
of the minimal assessment of cognitive function in multiple sclerosis
(MACFIMS) and the brief international cognitive assessment for multiple
sclerosis (BICAMS). Clin Neuropsychol. 2012;26(7):1186–200.
33. Walker LA, Osman L, Berard JA, Rees LM, Freedman MS, MacLean H,
Cousineau D. Brief international cognitive assessment for multiple sclerosis
(BICAMS): Canadian contribution to the international validation project. J
Neurol Sci. 2006;362:147–52.
34. Goretti B, Niccolai C, Hakiki B, Sturchio A, Falautano M, Minacapelli E, Amato
M. The brief international cognitive assessment for multiple sclerosis
(BICAMS): normative values with gender, age and education corrections in
the Italian population. BMC Neurol. 2014;14:171.
35. Sandi D, Rudisch T, Füvesi J, Fricska-Nagy Z, Huszka H, Biernacki T, Bencsik K.
The Hungarian validation of the brief international cognitive assessment for
multiple sclerosis (BICAMS) battery and the correlation of cognitive
impairment with fatigue and quality of life. Multiple Sclerosis and Related
Disorders. 2015;4:499–504.
36. O’Connell K, Langdon D, Tubridy N, Hutchinson M, McGuigan C. A
preliminary validation of the brief international cognitive assessment
for multiple sclerosis (BICAMS) tool in an Irish population with
multiple sclerosis (MS). Multiple Sclerosis and Related Disorders. 2015;
4:521–5.
37. Spedo CT, Frndak SE, Marques VD, Foss MP, Pereira DA, Carvalho L, Barreira
AA. Cross-cultural adaptation, reliability, and validity of the BICAMS in Brazil.
Clin Neuropsychol. 2015;29:836–46.
38. Giedraitienė N, Kizlaitienė R, Kaubrys G. The BICAMS battery for assessment
of Lithuanian-speaking multiple sclerosis patients: relationship with age,
education, disease disability, and duration. Med Sci Monit. 2015;21:3853–9.
39. Vanotti S, Smerbeck A, Benedict RHB, Caceres F. A new assessment tool for
patients with multiple sclerosis from Spanish-speaking countries: validation
of the Brief International Cognitive Assessment for MS (BICAMS) in
Argentina. Neurology. 2015;84(14):Suppl.P5. 201.
40. Costers L, Gielen J, Eelen PL, Schependom JV, Laton J, Remoortel AV,
Vanzeir E, Wijmeersch BV, Seeldrayers P, Haelewyck MC, D'Haeseleer M,
D'hooghe MB, Langdon D, Nagels G. Does including the full CVLT-II and
BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study.
Multiple Sclerosis Related Disorders. 2017;18:33–40.
41. Niino M, Fukazawa T, Kira JI, Okuno T, Mori M, Sanjo N, Ohashi T, Fukaura H,
Fujimori J, Shimizu Y, Mifune N, Miyazaki Y, Takahashi E, Kikuchi S, Langdon
Sousa et al. BMC Neurology  (2018) 18:172 Page 6 of 7
D, Hb Benedict R, Matsui M. Validation of the brief international cognitive
assessment for multiple sclerosis in Japan. Mult Scler J Exp Transl Clin. 2017;
26, 3(4).
42. Ozakbas S, Yigit P, Cinar BP, Limoncu H, Kahraman T, Kösehasanoğulları G.
The Turkish validation of the brief international cognitive assessment for
multiple sclerosis (BICAMS) battery. BMC Neurol. 2017;17:208.
Sousa et al. BMC Neurology  (2018) 18:172 Page 7 of 7
